High sensitivity C-reactive protein - A novel predictor for recurrence of atrial fibrillation after successful cardioversion

被引:108
作者
Malouf, JF [1 ]
Kanagala, R [1 ]
Al Atawi, FO [1 ]
Rosales, AG [1 ]
Davison, DE [1 ]
Murali, NS [1 ]
Tsang, TSM [1 ]
Chandrasekaran, K [1 ]
Ammash, NM [1 ]
Friedman, PA [1 ]
Somers, VK [1 ]
机构
[1] Mayo Clin, Coll Med, Div Cardiovasc Dis, Rochester, MN 55905 USA
关键词
D O I
10.1016/j.jacc.2005.06.053
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: We sought to test the hypothesis that C-reactive protein (CRP) can predict the recurrence of atrial fibrillation (AF) after successful electrical cardioversion (CV). Background: In patients with AF, CRP levels are predictive of immediate failure of CV. Methods: We prospectively measured high-sensitivity CRP in 67 patients with AF or atrial flutter who underwent successful electrical CV. Results: At one-month follow-up, 22 patients (33%) had recurrence of their arrhythmia. Arrhythmia recurrence was associated with significantly higher pre-CV CRP levels (odds ratio [OR] 1.84; 95% confidence interval [CI] 1.14 to 2.98; p = 0.013) even after adjusting for age (OR 2.22; 95% CI 1.25 to 3.93; p = 0.006), for gender (OR 1.89; 95% CI 1.16 to 3.09; p = 0.011), or duration of arrhythmia (OR 1.86; 95% CI 1.13 to 3.07; p = 0.015). On multivariate analysis, CRP was the only independent predictor of arrhythmia recurrence (OR 2.19; 95% CI 1.05 to 4.55; p = 0.036). Conclusions: Our data suggest that high levels of CRP are associated with an increased risk of recurrence of AF within one month. These data support the hypothesis that anti-inflammatory interventions may help in maintenance of normal sinus rhythm after CV. These data also may have implications for the identification of patients who are most likely to experience substantial benefit from CV therapy for AF.
引用
收藏
页码:1284 / 1287
页数:4
相关论文
共 16 条
[11]   Histological substrate of atrial biopsies in patients with lone atrial fibrillation [J].
Frustaci, A ;
Chimenti, C ;
Bellocci, F ;
Morgante, E ;
Russo, MA ;
Maseri, A .
CIRCULATION, 1997, 96 (04) :1180-1184
[12]   Comparison of recurrence rates after direct-current cardioversion for new-onset atrial fibrillation in patients receiving versus those not receiving rhythm-control drug therapy [J].
Li, HG ;
Riedel, R ;
Oldemeyer, JB ;
Rovang, K ;
Hee, T .
AMERICAN JOURNAL OF CARDIOLOGY, 2004, 93 (01) :45-48
[13]   Heart rate variability and early recurrence of atrial fibrillation after electrical cardioversion [J].
Lombardi, F ;
Colombo, A ;
Basilico, B ;
Ravaglia, R ;
Garbin, M ;
Vergani, D ;
Battezzati, PM ;
Fiorentini, C .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 37 (01) :157-162
[14]   Gender differences in C-reactive protein concentrations - Confirmation with two sensitive methods [J].
McConnell, JP ;
Branum, EL ;
Ballman, KV ;
Lagerstedt, SA ;
Katzmann, JA ;
Jaffe, AS .
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2002, 40 (01) :56-59
[15]   Analysis of Pravastatin to prevent recurrence of atrial fibrillation after electrical cardioversion [J].
Tveit, A ;
Grundtvig, M ;
Gundersen, T ;
Vanberg, P ;
Semb, AG ;
Holt, E ;
Gullestad, L .
AMERICAN JOURNAL OF CARDIOLOGY, 2004, 93 (06) :780-782
[16]   Beta-blockers prevent subacute recurrences of persistent atrial fibrillation only in patients with hypertension [J].
Van Noord, T ;
Tieleman, RG ;
Bosker, HA ;
Kingma, T ;
Van Veldhuisen, DJ ;
Crijns, HJGM ;
Van Gelder, IC .
EUROPACE, 2004, 6 (04) :343-350